Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran in adults with homozygous familial hypercholesterolemia
MOH_2019-02-14_005959Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2019
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in familial hypercholesterolemia (FH) comparing Inclisiran then open-label inclisiran with Placebo then switch to open-label inclisiran (2 arms). Started Jan 2019; status: completed.
02
Drugs
inclisiran
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on MOH_2019-02-14_005959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-02-14_005959.